It also said that it has "received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products." By the end of February the FDA had received more than 455 reports of adverse events with compounded semaglutide and more than 320 reports of adverse events with compounded tirzepatide
It is also important to consider medical supervision, laboratory monitoring, and individual response
In clinical trials, people who took Wegovy lost an average of 15% of their body weight in 68 weeks
[DOI] [PMC free article] [PubMed] [Google Scholar] 171.Zemba Cilic A., Zemba M., Cilic M., Strbe S., Ilic S., Vukojevic J., Zoricic Z., Filipcic I., Kokot A., Smoday I.M., et al
30 RabenMS